Viking Therapeutics Inc. (VKTX)
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note
Viking Therapeutics, Inc. (VKTX) closed at $36.15 in the latest trading session, marking a -2.51% move from the prior day.
Viking Therapeutics: Prepping For A Critical 2026
Viking Therapeutics is positioned for a pivotal 2026, advancing both injectable and oral VK2735 in obesity, with pipeline depth from an emerging amylin agonist program. VKTX's oral VK2735 has demonstrated unmatched double-digit weight loss in 13 weeks, potentially establishing leadership in the oral obesity drug segment. Despite a robust $714M cash position and a 4/5 conviction rating, risks include Phase III trial costs, competitive pressures, and potential dilution.
VKTX Stock Rises 34% in Three Months: Here's What You Should Know
Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Viking Therapeutics (VKTX) Up 1% Since Last Earnings Report: Can It Continue?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Viking Therapeutics, Inc. ( VKTX ) Jefferies London Healthcare Conference 2025 November 19, 2025 3:00 AM EST Company Participants Brian Lian - President, CEO & Director Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division All right. Welcome, everyone, to Jefferies Healthcare London Conference.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
AlphaQuest LLC Sells 2,913 Shares of Viking Therapeutics, Inc. $VKTX
AlphaQuest LLC cut its holdings in Viking Therapeutics, Inc. (NASDAQ: VKTX) by 24.8% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 8,840 shares of the biotechnology company's stock after selling 2,913 shares during the quarter. AlphaQuest LLC's holdings in Viking Therapeutics were worth $234,000
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Viking Therapeutics: High Risk, High Reward Play
Viking Therapeutics Inc. NASDAQ: VKTX stock is soaring after the company delivered its third-quarter earnings report. The clinical-stage biopharmaceutical company is not profitable and is not generating revenue.
